Poniard Pharmaceuticals, Inc.

OTCPK:PARD Stock Report

Market Cap: US$1.0

Poniard Pharmaceuticals Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownershipn/a
Management average tenureno data
Board average tenure17.3yrs

Recent management updates

No updates

Recent updates

No updates

CEO

Poniard Pharmaceuticals has no CEO, or we have no data on them.

Board Members

NamePositionTenureCompensationOwnership
Robert Littauer
Independent Director20.8yrsUS$116.50kno data
Frederick Craves
Director31.6yrsUS$94.00kno data
Alan Glassberg
Member of Clinical Advisory Boardno dataUS$211.67kno data
David Stevens
Independent Director20.8yrsUS$107.00kno data
Robert Basso
Independent Director17.8yrsUS$118.50kno data
Paul A. Bunn
Member of Clinical Advisory Boardno datano datano data
Skip Burris
Member of Clinical Advisory Board16.8yrsno datano data
E. Crawford
Member of Clinical Advisory Board16.8yrsno datano data
Everett Vokes
Member of Clinical Advisory Board16.8yrsno datano data
Robert Ozols
Member of Clincal Advisory Board16.8yrsno datano data
Eric Small
Member of Clinical Advisory Boardno datano datano data
Richard Goldberg
Member of Clinical Advisory Boardno datano datano data

17.3yrs

Average Tenure

78yo

Average Age

Experienced Board: PARD's board of directors are seasoned and experienced ( 17.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/14 11:15
End of Day Share Price 2024/12/27 00:00
Earnings2011/09/30
Annual Earnings2010/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Poniard Pharmaceuticals, Inc. is covered by 11 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason ZhangBMO Capital Markets U.S. (Historical)
Jonathan AschoffBrean Capital
George FarmerCanaccord Genuity